{"entity":{"id":"nct04452955","kind":"trial","name":"A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors","aka":[],"tldr":"A phase 2 trial of PRL3-zumab in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, active and no longer recruiting.","summary":"A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors is a phase 2 interventional study registered as NCT04452955 by Intra-IMMUSG Pte Ltd, with 51 participants enrolled, started 2020-12-12 and due to reach its primary completion in 2026-12-01. Interventions recorded: PRL3-zumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04452955","url":"https://clinicaltrials.gov/study/NCT04452955"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["intra-immusg","parexel"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04452955","phase":"2","setting":"An Open Label, Multicenter, Safety and Efficacy Phase 2 Study of PRL3-Zumab in Solid Tumors","sponsor":"Intra-IMMUSG Pte Ltd","enrolled":51,"outcomes":[]},"route":"/trials/nct04452955/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"intra-immusg","kind":"company","name":"Intra-IMMUSG","route":"/companies/intra-immusg/"},{"id":"parexel","kind":"company","name":"Parexel","route":"/companies/parexel/"}]}}